Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

NCT03754790 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

281

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia

Interventions

DRUG: Fitusiran

Sponsor

Genzyme, a Sanofi Company